528 related articles for article (PubMed ID: 28318053)
1. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
Chang FM; Wang YP; Lang HC; Tsai CF; Hou MC; Lee FY; Lu CL
Hepatology; 2017 Sep; 66(3):896-907. PubMed ID: 28318053
[TBL] [Abstract][Full Text] [Related]
2. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
Mohanty A; Tate JP; Garcia-Tsao G
Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
[TBL] [Abstract][Full Text] [Related]
3. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
5. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
Huang YW; Lee CL; Yang SS; Fu SC; Chen YY; Wang TC; Hu JT; Chen DS
Am J Gastroenterol; 2016 Jul; 111(7):976-85. PubMed ID: 27166128
[TBL] [Abstract][Full Text] [Related]
6. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
Yang YH; Chen WC; Tsan YT; Chen MJ; Shih WT; Tsai YH; Chen PC
J Hepatol; 2015 Nov; 63(5):1111-7. PubMed ID: 26196278
[TBL] [Abstract][Full Text] [Related]
7. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
9. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis.
Wong JC; Chan HL; Tse YK; Yip TC; Wong VW; Wong GL
Aliment Pharmacol Ther; 2017 Nov; 46(10):1001-1010. PubMed ID: 28940673
[TBL] [Abstract][Full Text] [Related]
10. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; José Ríos-Villegas M; Márquez-Solero M; Omar M; Macías J; Camacho A; Pérez-Pérez M; Gómez-Mateos J; Rivero A; Antonio Pineda J;
Hepatology; 2012 Jul; 56(1):228-38. PubMed ID: 22278746
[TBL] [Abstract][Full Text] [Related]
11. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis.
Kaplan DE; Serper MA; Mehta R; Fox R; John B; Aytaman A; Baytarian M; Hunt K; Albrecht J; Njei B; Taddei TH;
Gastroenterology; 2019 May; 156(6):1693-1706.e12. PubMed ID: 30660733
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis.
Toshikuni N; Izumi A; Nishino K; Inada N; Sakanoue R; Yamato R; Suehiro M; Kawanaka M; Yamada G
J Gastroenterol Hepatol; 2009 Jul; 24(7):1276-83. PubMed ID: 19486451
[TBL] [Abstract][Full Text] [Related]
13. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
[TBL] [Abstract][Full Text] [Related]
15. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
Trinchet JC; Bourcier V; Chaffaut C; Ait Ahmed M; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Buffet C; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Hillaire S; Di Martino V; Nahon P; Chevret S;
Hepatology; 2015 Sep; 62(3):737-50. PubMed ID: 25678021
[TBL] [Abstract][Full Text] [Related]
16. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
[TBL] [Abstract][Full Text] [Related]
17. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
18. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
[TBL] [Abstract][Full Text] [Related]
19. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
Tsan YT; Lee CH; Wang JD; Chen PC
J Clin Oncol; 2012 Feb; 30(6):623-30. PubMed ID: 22271485
[TBL] [Abstract][Full Text] [Related]
20. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance.
Cheung KS; Mak LY; Lam LK; Fung J; Liu F; Seto WK; Yuen MF
Hepatol Int; 2021 Aug; 15(4):881-891. PubMed ID: 33988834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
